Switching cannabinoid response from CB2 agonists to FAAH inhibitors - Archive ouverte HAL
Article Dans Une Revue Bioorganic and Medicinal Chemistry Letters Année : 2014

Switching cannabinoid response from CB2 agonists to FAAH inhibitors

Résumé

A series of 3-carboxamido-5-aryl-isoxazoles designed as CB2 agonists were evaluated as FAAH inhibitors. The pharmacological results led to identify structure-activity relationships enabling to switch cannabinoid response from CB2 agonists to FAAH inhibitors. Two compounds were selected for their FAAH and/or CB2 activity, and evaluated in a colitis model for their anti-inflammatory activity. Results showed that compounds 10 and 11 inhibit the development of DSS-induced acute colitis in mice and then, are interesting leads to explore new drug candidates for IBD.
Fichier non déposé

Dates et versions

hal-01935807 , version 1 (27-11-2018)

Identifiants

Citer

Aurélien Tourteau, Natascha Leleu-Chavain, Mathilde Body-Malapel, Virginie Andrzejak, Amelie Barczyk, et al.. Switching cannabinoid response from CB2 agonists to FAAH inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24 (5), pp.1322 - 1326. ⟨10.1016/j.bmcl.2014.01.056⟩. ⟨hal-01935807⟩
34 Consultations
0 Téléchargements

Altmetric

Partager

More